Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced ...

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the ...

Candidate profiles include HCC, liver metastases, and hepatic adenomas, including multifocal disease and stage IV patients who might otherwise be excluded from liver-directed interventions. Outpatient ...

Isabella Cueto covers the leading causes of death and disability: chronic diseases. Her focus includes autoimmune conditions and diseases of the lungs, kidneys, liver (and more). She writes about ...

A poster on the Effect of VS-01 on systemic inflammation and liver injury in a rat model of endotoxemia will also be presented by GENFIT. While VS-01 has been discontinued in ACLF, pre-clinical ...

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination ...

Chronic liver disease (CLD) is responsible for significant morbidity and mortality. Most liver-related outcomes occur in people with advanced CLD, yet liver disease can be asymptomatic until the late ...

Right Chemo, Wrong Route: Risks of Intrathecal Administration of Chemotherapy Forty-seven patients received intended complete treatment to 91 liver tumors. Three total complications were observed: two ...